AFT PHARMACEUTICALS LIMITED — Earnings Release 2021

May 23, 2021

==> picture [174 x 30] intentionally omitted <==

Results for announcement to the market	Results for announcement to the market	Results for announcement to the market	Results for announcement to the market
AFT Pharmaceuticals Limited
Reporting Period	12 months to 31 March 2021
Previous Reporting Period	12 months to 31 March 2020
Currency	NZ$
	Amount (000s)	Percentage change
Revenue from continuingoperations	$113,105	Up 7%
Total Revenue	$113,105	Up 7%
Net profit/(loss) from continuingoperations	$7,782	Down 40%
Total net profit/(loss)	$7,782	Down 39%
Interim/Final Dividend
Quoted Equity Securities:
Amount per Quoted EquitySecurity	No dividends have been paid on ordinary shares and it iscurrently not proposed to pay dividends.
Imputed amount per QuotedEquity Security	Not Applicable
Record Date	Not Applicable
Dividend Payment Date	Not Applicable
Unquoted Equity Securities:
Amount per UnquotedRedeemable Preference Share	4.7c for each payment
Imputed Amount per UnquotedRedeemable Preference Share	4.7c for each payment
Record Dates	20 May 2020, 30 June 2020 and 7 August 2020
Dividend Payment Dates	20 May 2020 and 7 August 2020
	Current period		Prior comparable period
Net tangible assets per QuotedEquity Security	$0.04		($0.10)
A brief explanation of any of thefigures above necessary toenable the figures to beunderstood	Accompanying this announcement are the Group’s auditedconsolidated financial statements for the twelve monthsended 31 March 2021. These financial statements and thefull year results commentary dated 24 May 2021 provide thebalance of information requirements in accordance with NZXListing Rule 3.5 and Appendix 2.Pursuant to ASX listing rule 1.15.3 AFT PharmaceuticalsLimited confirms that it continues to comply with the rules ofits home exchange (NZX Main Board).

	The unquoted Redeemable Preference Shares issued on 24March 2017 attracted a dividend rate of 9.4% per annum, or25.8 cents per share per annum. These were converted intoordinary shares by the holders during this accounting period.The dividends were paid in full in cash on or around theconversion dates and included in the above table.
Authority for this announcement
Name of person authorised tomake this announcement	Malcolm Tubby
Contact person for thisannouncement	Malcolm Tubby, Chief Financial Officer,AFT Pharmaceuticals Ltd
Contact phone number	+64 9 488 0232
Contact email address	malcolm@aftpharm.com
Date of release through MAP	24 May 2021

Audited financial statements accompany this announcement.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969